全文获取类型
收费全文 | 488329篇 |
免费 | 21529篇 |
国内免费 | 960篇 |
专业分类
耳鼻咽喉 | 6875篇 |
儿科学 | 17361篇 |
妇产科学 | 15890篇 |
基础医学 | 70334篇 |
口腔科学 | 13058篇 |
临床医学 | 39260篇 |
内科学 | 90035篇 |
皮肤病学 | 10631篇 |
神经病学 | 32899篇 |
特种医学 | 22140篇 |
外国民族医学 | 139篇 |
外科学 | 75270篇 |
综合类 | 9073篇 |
现状与发展 | 1篇 |
一般理论 | 168篇 |
预防医学 | 36069篇 |
眼科学 | 11078篇 |
药学 | 34563篇 |
30篇 | |
中国医学 | 972篇 |
肿瘤学 | 24972篇 |
出版年
2021年 | 2827篇 |
2018年 | 7784篇 |
2017年 | 6896篇 |
2016年 | 6821篇 |
2015年 | 8938篇 |
2014年 | 9549篇 |
2013年 | 11525篇 |
2012年 | 19344篇 |
2011年 | 14372篇 |
2010年 | 8871篇 |
2009年 | 9733篇 |
2008年 | 10977篇 |
2007年 | 12556篇 |
2006年 | 12585篇 |
2005年 | 20073篇 |
2004年 | 21092篇 |
2003年 | 16208篇 |
2002年 | 11052篇 |
2001年 | 17234篇 |
2000年 | 15256篇 |
1999年 | 16702篇 |
1998年 | 3603篇 |
1997年 | 3094篇 |
1996年 | 2994篇 |
1995年 | 2920篇 |
1992年 | 14480篇 |
1991年 | 14817篇 |
1990年 | 14829篇 |
1989年 | 14362篇 |
1988年 | 13129篇 |
1987年 | 12707篇 |
1986年 | 12158篇 |
1985年 | 11263篇 |
1984年 | 8038篇 |
1983年 | 6784篇 |
1982年 | 3396篇 |
1979年 | 7943篇 |
1978年 | 5412篇 |
1977年 | 4397篇 |
1976年 | 3934篇 |
1975年 | 5145篇 |
1974年 | 6220篇 |
1973年 | 5938篇 |
1972年 | 5707篇 |
1971年 | 5519篇 |
1970年 | 5242篇 |
1969年 | 4913篇 |
1968年 | 4649篇 |
1967年 | 4418篇 |
1966年 | 4060篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
5.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
6.
7.
Daniel Schar Pawin Padungtod Nguyen Tung Michael OLeary Wantanee Kalpravidh Filip Claes 《Influenza and other respiratory viruses》2019,13(6):618-621
Among the chief limitations in achieving early detection and control of animal‐origin influenza of pandemic potential in high‐risk livestock populations is the existing lag time between sample collection and diagnostic result. Advances in molecular diagnostics are permitting deployment of affordable, rapid, highly sensitive, and specific point‐of‐capture assays, providing opportunities for targeted surveillance driving containment strategies with potentially compelling returns on investment. Interrupting disease transmission at source holds promise of disrupting cycles of animal‐origin influenza incursion to endemicity and limiting impact on animal production, food security, and public health. Adoption of new point‐of‐capture diagnostics should be undertaken in the context of promoting robust veterinary services systems and parallel support for operationalizing pre‐authorized plans and communication strategies that will ensure that the full potential of these new platforms is realized. 相似文献
8.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献9.
10.
Marion Feldman Mayssa’ El Husseini Elisabetta Dozio Elise Drain Rahmeth Radjack Marie Rose Moro 《Child Care in Practice》2019,25(2):215-226
ABSTRACTClose observation of the interactions between a traumatised mother and her infant son provides information on the modes of transmission of psychic trauma in the mother–infant dyad. Following the presentation of a current literature review on the theme, the subject of “radioactive residue” and counter-transference in the transmission of psychic trauma from mother to infant will be illustrated through a clinical case study that focuses on a Haitian mother and her two-year-old infant son who has been referred to a “transitional care nursery” in urban Paris. The encounter with this mother–infant dyad is analysed through observing the quality of the interactions that take place between the mother and infant in order to determine how a particularly traumatic narrative impacts the mother–infant relationship, in addition to relations with the clinician. Mother and infant respond to one another through the emission and reception of “radioactive residues” as hypothesized by Gampel. This clinical case study shows that there is a need to consider transcultural factors and collective experience and history when analysing traumatic events. Additionally, the case study shows that counter-transference can be an effective clinical tool for gaining access to an infant's experience as the recipient of a traumatic narrative. 相似文献